FDA Grants IDE Approval to Dymicron for Triadyme-C Artificial Disc Trial

Dymicron has won U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) approval to begin a pivotal clinical study of its Triadyme–C cervical artificial disc.

The IDE approval allows the company to initiate a multi-center, prospective, historically controlled clinical trial comparing the safety and effectiveness of Triadyme-C to anterior cervical discectomy and fusion (ACDF) surgery in treating symptomatic cervical disc disease (SCDD). The trial will enroll patients across several U.S. spine centers, and the first implantations is slated for the fourth quarter this year.

“This FDA approval is a value-defining achievement for Dymicron,” Dymicron Board Chairman/CEO Alan S. Layton said. “It reflects both the strength of our technology and the disciplined execution of our regulatory roadmap. We are now poised to generate high-quality clinical data that will support a future PMA submission and lay the groundwork for commercialization in the U.S. market.”

“The Triadyme-C represents a remarkable advancement in cervical disc technology. Its revolutionary polycrystalline diamond bearing surfaces dramatically reduce wear debris generation, while the tri-lobed design is engineered to closely replicate normal spinal kinematics—two factors that could improve long-term outcomes for patients,” stated Richard Guyer, M.D., co-director, Center for Disc Replacement, Texas Back Institute in Plano, Texas, and co-primary investigator for the Triadyme-C IDE trial.

The Triadyme–C device features bearing surfaces made from Adymite, Dymicron’s proprietary medical grade polycrystalline diamond material. Adymite was developed specifically for high-stress load-bearing environments and is engineered to dramatically reduce wear debris generation compared to conventional implant materials such as titanium, cobalt-chromium, and polyethylene—an issue linked to long-term device complications and revision surgeries. The result is a construct with exceptional hardness, low friction, and long-term articulation performance, optimized for the lifetime demands of spinal motion preservation, according to the company.

“We believe Adymite represents a platform technology with long-term strategic value across multiple medical applications,” Layton added. “Our core IP portfolio, proprietary manufacturing capabilities, and strong clinical positioning give us a powerful foundation for growth. We look forward to validating our technology in this pivotal U.S. trial.”

The trial’s composite clinical success primary endpoint will be defined by: Neck Disability Index (NDI) Score improvement, mMaintenance or improvement in neurological status, and the absence of secondary surgical interventions.

Trial data will support a future Premarket Approval (PMA) submission to the FDA.

“IDE approval for the Triadyme-C marks a pivotal milestone in advancing this next-generation cervical disc toward the U.S. market,” said Pierce Nunley, M.D., founder and medical director of the Spine Institute of Louisiana and Triadyme-C co-primary investigator. “A key factor distinguishing spine arthrodesis products is wear debris, which can trigger varying degrees of osteolysis and potential implant failure. With its proprietary polycrystalline diamond material designed to virtually eliminate wear debris, and a tri-lobed geometry engineered to restore natural motion, Triadyme-C stands to set a new benchmark in long-term implant performance and market differentiation.”

The Triadyme-C is a next-generation, motion-preserving cervical artificial disc made of Adymite (polycrystalline diamond), one of the most wear-resistant materials known to humans. The Tri­adyme-C produces virtually no detectable wear debris, minimizing the risk of any wear debris-related complications, and optimizing performance for the patient’s lifetime. The Triadyme-C’s patented Tri-Lobe design mimics a disc’s natural kinematics and motion.

Dymicron is a privately held company based in Orem, Utah.